Statin use and mortality in the bacteremic critically ill patient

Critical Care Medicine

Volumn 34, Issue 4, 2006, Pages 1270-1272

  Corona, Alberto ^a,b,c   Raimondi, Ferdinando ^c   Singer, Mervyn ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Bacteraemia; Intensive care unit; Mortality; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

BACTEREMIA; COMMUNICABLE DISEASE; CRITICALLY ILL PATIENT; DRUG EFFECT; DRUG EFFICACY; EDITORIAL; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS;

BACTEREMIA; CRITICAL ILLNESS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 33645807846     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000208353.21157.A0     Document Type: Editorial

References (17)

1. Thomsen RW, Hundborg HH, Johnsen SP, et al: Statin use and mortality within 180 days after bacteremia: A population-based cohort study. Crit Care Med 2006; 34:1080-1086
2. Walley T, Folino-Gallo P, Schwabe U, et al: Comparison of national administrative and commercial databases to monitor expenditure and costs of statins across Europe. Eur J Clin Pharmacol 2004; 60:503-511
3. Gui D, Spada PL, De Gaetano A, et al: Hypocholesterolemia and risk of death in the critically ill surgical patient. Intensive Care Med 1996; 22:790-794
4. Goldstein JL, Brown MS: Regulation of the mevalonate pathway Nature 1990; 343:425-430
5. Rosenson RS, Tangney CC: Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA 1998; 279:1643-1650
6. Kwak BR, Mach F: Statins inhibit leukocyte recruitment: New evidence for their anti-inflammatory properties. Arterioscler Thromb Vasc Biol 2001; 21:1256-1258
7. Almog Y: Statins, inflammation, and sepsis: Hypothesis. Chest 2003; 124:740-743
8. Tai SC, Robb GB, Marsden PA: Endothelial nitric oxide synthase: A new paradigm for gene regulation in the injured blood vessel. Arterioscler Thromb Vasc Biol 2004; 24:405-412
9. Liappis AP, Kan VL, Rochester CG, et al: The effect of statins on mortality in patients with bacteraemia. Clin Infect Dis 2001; 33:1352-1357
10. Almog Y, Shefer A, Novack V, et al: Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004; 110:880-885
11. Mortensen EM, Restrepo MI, Anzueto A, et al: The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res 2005; 25:82
12. Kruger P, Fitzsimmons K, Cook D, et al: Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 2005 Nov 10 [Epub ahead of print]
13. Fernandez R, De Pedro VJ, Artigas A: Statin therapy prior to ICU admission: Protection against infection or a severity marker? Intensive Care Med 2006; 34:160-164
14. Van den Berghe G, Wouters P, Weekers F, et al: Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345:1359-1367
15. Griffiths RD, Jones C, Palmer TE: Six-month outcome of critically ill patients given glutamine-supplemented parenteral nutrition. Nutrition 1997; 13:295-302
16. National Institute for Health and Clinical Excellence Final Appraisal Detemination Statins for the Prevention of Cardiovascular Events: Available at http://www.nice.org.uk/pdf/word/Final%20FAD%20for%20Consultation%2003%2011%2005. doc
17. Stagnitti MN: Statin use among persons 18 and older in the U.S. civilian noninstitutionalized population reported as receiving medical care for the treatment of high cholesterol, 2002 Medical Expenditure Panel Survey - Agency for Healthcare Research and Quality. Available at http://www.meps.ahrq.gov/ papers/st95/stat95.pdf